Skip to main content

2013 | OriginalPaper | Buchkapitel

3. The History of OPEX in the Pharmaceutical Industry

verfasst von : Thomas Friedli, Jürgen Werani

Erschienen in: Leading Pharmaceutical Operational Excellence

Verlag: Springer Berlin Heidelberg

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

The History of Operational Excellence in the Pharmaceutical Industry is still short. Serious initiatives were only launched around 10 years ago. This chapter provides some background on how and why OPEX became a topic of serious interest in this industry.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Fußnoten
1
FDA, Final Report “Pharmaceutical CGMPs for the 21st Century – A Risk-Based Approach”, September 2004.
 
2
Guidance for Industry PAT – A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, FDA, September 2004, Page 3.
 
3
Janet Woodcock (2011).
 
4
Bruttin and Dean (2004).
 
5
Cf. Report of the PAT Team and Manufacturing Science Working Group 2004, Page 1.
 
6
Cf. Clark (2004): FDA’s PAT initiative, in: Pharmaceutical Technology Europe.
 
7
Clark (2004).
 
8
Cf. Report of the PAT Team and Manufacturing Science Working Group 2004.
 
9
FDA 2004b.
 
10
FDA 2004b.
 
Literatur
Zurück zum Zitat FDA (2004a) Challenge and opportunity on the critical path to new medical products. www.fda.gov. Retrieved January 2010 FDA (2004a) Challenge and opportunity on the critical path to new medical products. www.​fda.​gov. Retrieved January 2010
Zurück zum Zitat FDA (2004b) Final report “pharmaceutical CGMPs for the 21st century – a risk-based approach”, September 2004. www.fda.gov. Retrieved January 2010 FDA (2004b) Final report “pharmaceutical CGMPs for the 21st century – a risk-based approach”, September 2004. www.​fda.​gov. Retrieved January 2010
Zurück zum Zitat Gronauer T, Friedli T, Götzfried M (2010) The roadmap to operational excellence – pattern and elements of OPEX programs. In: Friedli et al. (2010) The pathway to operational excellence – overcoming the internal inertia. Editio Cantor Verlag, Aulendorf Gronauer T, Friedli T, Götzfried M (2010) The roadmap to operational excellence – pattern and elements of OPEX programs. In: Friedli et al. (2010) The pathway to operational excellence – overcoming the internal inertia. Editio Cantor Verlag, Aulendorf
Zurück zum Zitat Kickuth M, Friedli T (2006) The pharmaceutical plant of the future. In: Friedli T, Kickuth M, Stieneker F, Thaler P, Werani J (eds) Operational excellence in the pharmaceutical industry. ECV – Ed.-Cantor-Verl, Aulendorf Kickuth M, Friedli T (2006) The pharmaceutical plant of the future. In: Friedli T, Kickuth M, Stieneker F, Thaler P, Werani J (eds) Operational excellence in the pharmaceutical industry. ECV – Ed.-Cantor-Verl, Aulendorf
Zurück zum Zitat Report of the PAT Team and Manufacturing Science Working Group (2004) Innovation and continuous improvement in pharmaceutical manufacturing – pharmaceutical CGMPs for the 21st century. www.fda.gov. Retrieved January 2010 Report of the PAT Team and Manufacturing Science Working Group (2004) Innovation and continuous improvement in pharmaceutical manufacturing – pharmaceutical CGMPs for the 21st century. www.​fda.​gov. Retrieved January 2010
Zurück zum Zitat Woodcock J (2011) Presentation, meeting of the FDA science board, November 16th, FDA, Regulation of drug quality: new challenges. www.fda.gov. Retrieved 20 January 2013 Woodcock J (2011) Presentation, meeting of the FDA science board, November 16th, FDA, Regulation of drug quality: new challenges. www.​fda.​gov. Retrieved 20 January 2013
Metadaten
Titel
The History of OPEX in the Pharmaceutical Industry
verfasst von
Thomas Friedli
Jürgen Werani
Copyright-Jahr
2013
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-642-35161-7_3